Skip to main content

Table 1 Clinicopathologic features of the 131 patients at the time of surgery

From: Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective

Parameters

Total (n = 131)

UFS (n = 64)

NAC (n = 67)

NAC (GS) (n = 62)

P value (UFS v.s. NAC)

P value (UFS v.s. NAC (GS))

Median age (range)

69 (43-90)

69 (46-90)

69 (43-84)

68 (43-84)

0.163

0.105

Sex

 Male

72

38

34

32

0.381

0.473

 Female

59

26

33

30

Date of surgery

 Before 2014

42

39

3

1

< 0.001

< 0.001

 2014 and later

89

25

64

61

Tumor location

 Head

79

43

36

34

0.153

0.201

 Body and tail

52

21

31

28

Tumor size

 pT1

25

8

17

16

0.076

0.071

 pT2/pT3

106

56

50

46

Tumor size

 pT1/pT2

113

55

58

54

1.000

1.000

 pT3

18

9

9

8

Differentiation grade

 G1/G2

112

52

60

55

0.218

0.321

 G3/G4

19

12

7

7

Differentiation grade

 G1

56

27

29

27

1.000

1.000

 G2/G3/G4

75

37

38

35

Microvascular invasion

 Positive

115

59

56

51

0.397

0.261

 Negative

14

5

9

9

 Unknown

2

0

2

2

  

Lymphatic permeation

 Positive

96

49

47

43

0.436

0.424

 Negative

35

15

20

19

Perineural invasion

 Positive

111

56

55

50

0.470

0.336

 Negative

20

8

12

12

Nodal metastasis

 pN0

50

20

30

28

0.015

0.005

 pN1

57

26

31

30

 pN2

24

18

6

4

Distant metastasis

 Yes

5

5

0

0

0.026

0.058

 No

126

59

67

62

TNM stage

 I/II

104

43

61

58

0.001

< 0.001

 III/IV

27

21

6

4

R0 resection

 Yes

80

35

45

44

0.156

0.067

 No

51

29

22

18

R2 resection

 Yes

1

0

1

1

1.000

0.492

 No

130

64

66

61

Surgery-related death

 Yes

2

2

0

0

0.237

0.496

 No

129

62

67

62

Postoperative chemotherapy

 Yes

113

54

59

54

0.271

0.399

 No

14

9

5

5

 Unknown

4

1

3

3

  

Postoperative radiotherapy

 Yes

7

3

4

4

1.000

0.715

 No

124

61

63

58

  1. NAC neoadjuvant chemotherapy, UFS upfront surgery, GS gemcitabine plus S-1 (tegafur/gimeracil/oteracil), G1 well differentiated carcinoma, G2 moderately differentiated carcinoma, G3 poorly differentiated carcinoma, G4 undifferentiated carcinoma, R0 microscopically invasive cancer-free, R2 macroscopically residual tumor